
About VyantBio
VyantBio is a Healthcare company based in Cherry Hill (United States) founded in 1999. VyantBio has raised $10.5 million across 4 funding rounds from investors including National Science Foundation. The company has 25 employees. Its focus areas include Life Sciences, Life Sciences Platforms and Tools, Research Assays and Drug Discovery. Its legal entity is VYANT BIO, INC. Its competitors include Vivodyne, Adapsyn and Parallel Bio; 2 of its 3 listed competitors have raised funding.
Company details
Developer of drug discovery platform. The company has an AnalytiX platform to identify drug candidates, targets, and biomarkers with the help of human biology and machine learning. The company is developing human disease models and drugs for multiple diseases.
- Headquarters Cherry Hill, United States
- Employees 25
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website vyantbio.com
- Social LinkedIn X
- Legal Name Vyant Bio, Inc.
- Annual Revenue$666 K (USD)-42as on Dec 31, 2022
- Total Equity Funding$10.5M (USD)
in 4 rounds
- Latest Funding Round$5.5M (USD), Series A
Sep 2016
- Investors
- Employee Count25
Funding Insights of VyantBio
VyantBio has successfully raised a total of $10.5M across 4 strategic funding rounds. The most recent funding activity was a Series A round of $5.5 million completed in September 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $10.5M
- Total Rounds 4
- Last Round Series A β $5.5M
- First Round $150,000
(Jul 2007)
- Investors Count 1
All 4 funding rounds of VyantBio with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2016 | $5.5M | Series A | β | β | β |
| May 2016 | $5M | Series A | β | β | β |
| Apr 2009 | $600,000 | Grant | β | β | |
| Jul 2007 | $150,000 | Grant | β | β |
1 investors in total: 1 institutional.
Investors in VyantBio
VyantBio has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include National Science Foundation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A government-backed foundation providing seed-stage investments to support small businesses. | 1950 | nsf.gov | Arlington, United States |
Investor details for VyantBio
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of VyantBio
14 people are tracked at VyantBio (6 in leadership, 6 in board & advisors, 2 in team); the tracked headcount is 25.
| Name | Role | Group |
|---|---|---|
Jay Roberts | President & CEO | Leadership |
Andrew D.C. Lafrence | CFO | Leadership |
Robert T. Fremeau | Chief Scientific Officer | Leadership |
Robert Torka | Director Business Development Europe | Leadership |
Melanie Keller | Division Head Europe | Leadership |
William Davis | Director of Clinical Sales East | Leadership |
John Fletcher | Chairman | Board & advisors |
Geoffrey Harris | Director | Board & advisors |
Joanna Horobin | Director | Board & advisors |
Paul Hansen | Director | Board & advisors |
Howard Mcleod | Director | Board & advisors |
Ping Yeh | Director | Board & advisors |
Carol Walling | Clinical Sales Specialist | Team |
Mijanou van der Woude | Site Operations Manager | Team |
Complete people profiles for VyantBio
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of VyantBio
3 dated milestones of VyantBio across 17 years, from founding to its latest funding, stage changes and deals.
- Founded VyantBio is founded.
- Funding First funding round of $150K.
- Funding Latest funding round, Series A, of $5.5M.
Competitors of VyantBio
VyantBio has 3 listed competitors in our database, 2 of them funded. They include Vivodyne, Adapsyn and Parallel Bio.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| vivodyne.com | 2021 | Philadelphia, United States | $117.69M | Developer of AI-based platform for lab-grown human tissues | ||
| adapsyn.com | 2016 | Hamilton, United States | Provider of computational tools for bacterial metabolomic and genomic data analysis | |||
| parallel.bio | 2020 | Cambridge, United States | $25.43M | 6 | Limited information available |
Detailed competitors of VyantBio
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Top companies in Life Sciences Platforms & Tools
3 companies that operate in the same segment as VyantBio (Life Sciences Platforms & Tools) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | |||
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | 1,111 | ||
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Vyantbio
Complete news archive for VyantBio
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about VyantBio
VyantBio was founded in 1999 and raised its 1st funding round 8 years after it was founded.
VyantBio is headquartered in Cherry Hill, United States. It is registered at Cherry Hill, New Jersey, United States.
VyantBio is a funded company, having raised a total of $10.5M across 4 funding rounds to date. The company's 1st funding round was a Grant of $150K, raised on Jul 2007.
VyantBio has 25 employees.
Annual revenue of VyantBio is $666K as on Dec 31, 2022.
Developer of drug discovery platform. The company has an AnalytiX platform to identify drug candidates, targets, and biomarkers with the help of human biology and machine learning. The company is developing human disease models and drugs for multiple diseases.
VyantBio's top competitors include Vivodyne, Parallel Bio and Adapsyn.
VyantBio has 1 investor. Key investors include National Science Foundation.
VyantBio operates through Vyant Bio, Inc..
